Pediatric Hematology Oncology Clinical Trials Unit
Hydroxyurea Optimization through Precision Study (HOPS)
AGE: 6 months - 21 years old
GENDER: All
GENDER: All
TYPE: Intervention Study
CONDITION: Sickle Cell Anemia
CONDITION: Sickle Cell Anemia
LOCATION: UH Rainbow Babies & Children’s Hospital
Learn More About This Research Study
For more information, please call study coordinator, Mandy Rivera, at 216-844-4908 or by completing the form below.
Study Purpose
The purpose of this study is to compare the standard dosing of hydroxyurea to a new individualized way of dosing to determine whether the new dosing strategy can result in better results. Hydroxyurea is normally dosed based only on your weight. This study will select a starting dose based on how each patient absorbs hydroxyurea.
Who Can Participate
Patients 6 months of age to 21 years of age diagnosed with sickle cell anemia (HbSS, HbSD, HbS/B-thalassemia, or similarly severe SCA) may be eligible for to participate in this study.
- STUDYID20190803